Mapmygenome is a genomics startup based in Hyderabad, India, that offers personal genetic testing and molecular diagnostics for consumers.

This Startup Deep Dive explains what Mapmygenome does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Mapmygenome in Brief

• What it is: Mapmygenome is an Indian Consumer genomics and wellness company based in Hyderabad.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Its flagship Genomepatri uses a saliva test to estimate genetic predisposition to 120+ conditions plus traits, drug responses and lifestyle factors, with genetic counselling.
• The company also offers molecular diagnostics, brain wellness (Mapmybrain, developed with Brain Resource) and TB diagnostic kits.
• It ran Covid testing through two approved labs in Hyderabad.
• Funding: Reported: about $2.3M+ per one database; another shows $1.11M over 2 rounds.

Mapmygenome Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Mapmygenome?

Mapmygenome operates in the Consumer genomics and wellness space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Mapmygenome.

• Its flagship Genomepatri uses a saliva test to estimate genetic predisposition to 120+ conditions plus traits, drug responses and lifestyle factors, with genetic counselling.
• The company also offers molecular diagnostics, brain wellness (Mapmybrain, developed with Brain Resource) and TB diagnostic kits.
• It ran Covid testing through two approved labs in Hyderabad.

The Origin Story of Mapmygenome

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Anu Acharya.
• Anu Acharya founded the company after experience at Ocimum Biosolutions; it is described as one of India's first direct-to-consumer genomics companies.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Consumer genomics and wellness sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2015: Pre-Series A round with angels including Rajan Anandan and Arihant Patni (reported).

Mapmygenome Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Reported: 2015 pre-Series A of over INR 7 Cr, or $1.1M per another report, from angels including Aarti Grover, Rajan Anandan and Arihant Patni.
• Reported: a seed round dated December 2019 and an angel round in 2020 appear in one database, amounts not seen.

How Does Mapmygenome Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Revenue sources: The exact revenue mix of Mapmygenome is not disclosed in public sources reviewed.
• What to look for: Recurring contracts, repeat customers, gross margin trend and payback on customer acquisition.

The Numbers: Mapmygenome Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Revenue of INR 31.2 Cr+ for FY25 per one database; another gives only an estimated range of $1M to $10M (reports differ).
• Anu Acharya held 68.7% as of 31 March 2022 per one source; another puts founders collectively at 74.8%.

Market Opportunity for Mapmygenome

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Demand drivers: rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings.
• Reach: How much of the market Mapmygenome can serve depends on its product readiness, distribution and regulatory approvals.

Technology and Product at Mapmygenome

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Core capability: Public detail on Mapmygenome’s technology stack is limited beyond company-stated descriptions.
• Assessment lens: clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

Team and Culture at Mapmygenome

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Leadership: Anu Acharya are named as founders.
• Further detail on the wider team is limited in public sources.

Mapmygenome Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of Mapmygenome vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for Mapmygenome

• Revenue and funding figures come from third-party databases and conflict, so traction is hard to verify.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.
• Thin margins: low-ticket services and heavy customer-acquisition spend can keep unit economics weak.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Mapmygenome Growth Outlook: What to Watch

• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Mapmygenome can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Mapmygenome Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Mapmygenome

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Mapmygenome.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Mapmygenome

Studying a company in the Consumer genomics and wellness space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Mapmygenome.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Mapmygenome as a Startup

• Customer clarity: Can Mapmygenome name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Mapmygenome is part of India’s growing Consumer genomics and wellness ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Mapmygenome FAQs: Frequently Asked Questions

What is Mapmygenome?

Mapmygenome is a genomics startup based in Hyderabad, India, that offers personal genetic testing and molecular diagnostics for consumers. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Mapmygenome?

Mapmygenome was founded by Anu Acharya, and the company reports a founding year of 2013 (reports differ: 2011, 2012 and 2013).

How much funding has Mapmygenome raised?

Reported: about $2.3M+ per one database; another shows $1.11M over 2 rounds. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Mapmygenome make money?

Mapmygenome earns revenue from its Consumer genomics and wellness products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Mapmygenome?

Competitors of Mapmygenome depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for Mapmygenome?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Sugar.fit — Sugar.fit: revenue up 77% to Rs 66.5 crore in FY25 | YourDOST — YourDOST: online counselling for colleges and corporates. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.